Introducing Crowell & Moring’s Compliance “Check-Up” for Government Contractors
Client Alert | 1 min read | 03.06.18
The Government Contracts and Corporate Groups at Crowell & Moring LLP are pleased to announce our Compliance “Check-Up” for Government Contractors, focused on providing pre-sale advice to government contractors and private equity sponsors contemplating selling or fundraising in the current market. Our team of over 80 experienced government contracts and transactional professionals stands ready to assist clients by providing (at no cost) a “Check-Up” – a diagnostic review of key diligence questions, aimed at identifying common compliance issues that can drive down sales prices and/or increase borrowing costs. By identifying these issues early in the diligence process, sellers can avoid common traps that may negatively impact deal terms, complicate reps and warranties, and make post-merger integration more difficult and expensive. For more information on our Compliance “Check-Up” for Government Contractors, please click here.
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 8 min read | 06.30.25
AI Companies Prevail in Path-Breaking Decisions on Fair Use
Last week, artificial intelligence companies won two significant copyright infringement lawsuits brought by copyright holders, marking an important milestone in the development of the law around AI. These decisions – Bartz v. Anthropic and Kadrey v. Meta (decided on June 23 and 25, 2025, respectively), along with a February 2025 decision in Thomson Reuters v. ROSS Intelligence – suggest that AI companies have plausible defenses to the intellectual property claims that have dogged them since generative AI technologies became widely available several years ago. Whether AI companies can, in all cases, successfully assert that their use of copyrighted content is “fair” will depend on their circumstances and further development of the law by the courts and Congress.
Client Alert | 3 min read | 06.30.25
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
